Bogani G, et al. - Researchers analyzed factors predictive of morbidity, readmission, and cost in patients undergoing pelvic exenteration for recurrent gynecological malignancies. Data of consecutive patients undergoing pelvic exenteration between January 2007 and December 2016 suggested no influence of radiotherapy dosage, time between radiotherapy and surgery, and previous administration of chemotherapy on 90-day complications and readmission. Multivariable analysis indicated the association of albumin levels <3.5 g/dL and history of deep vein thrombosis with 90-day morbidity. Readmission was noted in independent correlation with low albumin levels. Increases in costs by a median of +12,500 and +6,000 euros were noted with the occurrence of 90-day postoperative complications and readmission, respectively.